Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics

NCT04137055 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2021-07-28

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single-and multiple-oral doses of ZSP0678 on fasted condition, and characterize PK of ZSP0678 on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts (Ascending single dose, multiple dose and food effect). Participants will receive either ZSP0678 or placebo .

Conditions

Interventions

DRUG

ZSP0678-10mg

ZSP0678 tablet administered orally under fasted condition

DRUG

ZSP0678-30mg

ZSP0678 tablets administered orally under fasted condition

DRUG

ZSP0678-60mg

ZSP0678 tablets administered orally under fasted condition

DRUG

ZSP0678-120mg

ZSP0678 tablets administered orally under fasted condition

DRUG

ZSP0678-180mg

ZSP0678 tablets administered orally under fasted condition

DRUG

ZSP0678-240mg

ZSP0678 tablets administered orally under fasted condition

DRUG

ZSP0678-320mg

ZSP0678 tablets administered orally under fasted condition

DRUG

ZSP0678

ZSP0678 tablets administered orally under fasted or fed condition

DRUG

ZSP0678-Dose 1

ZSP0678 tablets administered orally once daily for 14 Days

DRUG

ZSP0678-Dose 2

ZSP0678 tablets administered orally once daily for 14 Days

DRUG

ZSP0678-Dose 3

ZSP0678 tablets administered orally once daily for 14 Days

DRUG

ZSP0678 Placebo

Participants will receive placebo matching to ZSP0678 orally.

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2020-12-09
Completion
2020-12-09

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04137055 on ClinicalTrials.gov